Moleculin Biotech, Inc. (NASDAQ:MBRX) Short Interest Update

Moleculin Biotech, Inc. (NASDAQ:MBRX) saw a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 107,000 shares, a growth of 108.6% from the August 15th total of 51,300 shares. Approximately 3.9% of the company’s stock are sold short. Based on an average daily trading volume, of 32,000 shares, the short-interest ratio is presently 3.3 days.

Analyst Ratings Changes

Separately, StockNews.com started coverage on Moleculin Biotech in a research report on Tuesday, September 10th. They set a “sell” rating on the stock.

Hedge Funds Weigh In On Moleculin Biotech

An institutional investor recently bought a new position in Moleculin Biotech stock. Armistice Capital LLC acquired a new position in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 3,207,417 shares of the company’s stock, valued at approximately $2,753,000. Armistice Capital LLC owned approximately 9.60% of Moleculin Biotech as of its most recent filing with the SEC. 15.52% of the stock is currently owned by institutional investors.

Moleculin Biotech Stock Performance

Shares of Moleculin Biotech stock remained flat at $2.43 on Friday. The stock had a trading volume of 15,437 shares, compared to its average volume of 29,181. The stock’s fifty day moving average is $2.90 and its 200 day moving average is $4.51. Moleculin Biotech has a 1-year low of $2.12 and a 1-year high of $15.75.

Moleculin Biotech (NASDAQ:MBRX) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($2.23) EPS for the quarter, missing the consensus estimate of ($2.10) by ($0.13). On average, sell-side analysts predict that Moleculin Biotech will post -8.6 earnings per share for the current fiscal year.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.